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between erbB3 and IRS-1 in MCF-7, T47-D and BT-474 cells with
HRGb1 treatment enhancing this recruitment and promoting
IRS-1 phosphorylation at tyrosine (Y) 612, a specific PI3-K binding
site. In addition, siRNA knockdown of IRS-1 greatly impaired
HRGb1 signalling via PI3-K/AKT in these cells. This novel interac-
tion may have clinical relevance as immunohistochemical analy-
sis of ER-positive BC patient samples revealed IRS-1 Y612
expression positively correlated with total erbB3, p-AKT and
Ki67 expression. Importantly, we found that association of IRS-1
by erbB3 impaired IRS-1 recruitment by IGF-IR in both MCF-7
and T47D cells, whilst blockade of IGF-1R enhanced erbB3/IRS-1
interaction and sensitised both cell lines to HRGb1. Consequently,
knockdown of IRS-1 reduced HRGb1 action and enhanced the
effects of IGF-IR inhibition in these cells. In conclusion, these
and previous findings suggest that IRS-1 can be recruited to IGF-
1R, EGFR and erbB3 in ER-positive BC cells and this may provide
an adaptive resistance mechanism when these receptors are tar-
geted individually. Consequently co-targeting of IGF-IR and erbB
receptors/IRS-1 may prove to be a more effective strategy for
the treatment of ER-positive BC.
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Human Epidermal Receptor 2 (HER2)+ have attracted attention
as a poor prognostic class of breast cancer. However, HER2+
tumours appear to encompass biologically and clinically hetero-
geneous tumours.
In order to refine HER2+ breast cancer, we analysed over 48,000
gene transcripts in 132 invasive breast carcinomas using Artificial
Neural Network analysis and identified high expression of two
novel genes (SOX11, PSMD3) significantly associated HER2+ posi-
tivity. Using a large invasive breast carcinoma cohort (n = 1,298),
prepared as tissue microarrays, we assessed these targets using
immunohistochemistry and investigated associations with clini-
copathological variables, patients’ outcome and ability to refine
HER2+ classification.
PSMD3 nuclear expression was observed in 219/942 (23%) of
tumours and was significantly correlated to HER2 positivity
(p = 0.004), tubule formation (p = 0.047) and NPI (p = 0.007). PSMD3
expression conferred a strong trend towards a longer breast can-
cer specific survival in the whole series (p = 0.065). SOX11 nuclei
staining was observed in 96/869 (3.8%) tumours and was signifi-
cantly associated with ER (p = 0.006) and PSMD3 nuclear
(p < 0.001) positivity and ck14 negativity (p = 0.018) but not HER2.
SOX11 expression did not predict patient clinical outcome in
either the whole series or HER2+ tumours only.
This study confirms the biological and clinical heterogeneity
of HER2+ tumours and the difficulties in translating global gene
expression data into routine practice using immunohistochemis-
try. We have identified two novel genes associated with HER2+
tumours and further studies analysing the role of PSMD3 expres-
sion in this important subtype is warranted.
doi:10.1016/j.ejcsup.2010.06.038
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Introduction: Recent seminal findings from our institution indi-
cate that systemic miR-195 and Let-7a levels have potential as
non-invasive breast cancer biomarkers. We aimed to validate
these findings in an expanded cohort and to identify further miR-
NAs which augment the sensitivity and specificity of circulating
miRNAs as diagnostic and prognostic markers for breast cancer.
Methods: The expression levels of nine miRNAs were evaluated
in an expanded cohort of 265 breast cancer patients, 80 non-
breast malignancies (colon, renal, prostate and melanoma) and
63 age-matched disease-free controls using RQ-PCR. Eleven addi-
tional miRNAs were evaluated as potential miRNA endogenous
controls. Advanced QBase plus software and SPSS were used for
biostatistical analysis of the data and correlation with clinico-
pathological variables.
Results: This study confirmed significantly deranged expres-
sion levels of systemic miR-195 and Let-7a and two additional
miRNAs in breast cancer patients compared to disease-free con-
trols. Elevated miR-195 was identified to be breast cancer-specific,
with a sensitivity of 88% and a specificity of 91%. A combination
of three circulating miRNAs, including miR-195 and Let-7a,
increased the discriminatory power of this test for breast cancer
to 94%. Of the eleven candidate miRNAs selected for normalisa-
tion, two were identified to be stably expressed in a subset of
the original cohort and thus are ideal endogenous controls for
blood based miRNA studies.
Conclusion: This study highlights the presence and dysregula-
tion of cancer-specific miRNAs in the circulation of breast cancer
patients and illustrates the potential for this systemic miRNA sig-
nature to aid in the diagnosis and prognostication of this disease.
doi:10.1016/j.ejcsup.2010.06.039
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